ArticleCureus2026
Histomorphological and Immunohistochemical Profile of Malignant Breast Lesions in a Tertiary Care Center of Central India: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast carcinoma is a heterogeneous malignancy with variable histomorphological patterns and immunohistochemical profiles. Evaluation of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) expression provides important prognostic and predictive information for treatment planning. Ki-67 was not evaluated in the present study; therefore, the reported immunohistochemical subgroups were based only on ER, PR, and HER2/neu expression. This study aimed to assess the histomorphological and immunohistochemical profile of malignant breast lesions in a tertiary care center in Central India.
methodsThis cross-sectional observational study included 84 patients with histopathologically confirmed malignant breast lesions. Tumors were classified according to standard histopathological criteria and graded using the Nottingham modification of the Bloom-Richardson system. Immunohistochemistry was performed for ER, PR, and HER2/neu. Molecular subtypes were assigned based on ER, PR, and HER2/neu expression.
resultsThe most common age group was 41-50 years (n = 39, 46.4%). Invasive ductal carcinoma, not otherwise specified, accounted for 95.2% (80/84) of cases. Grade III tumors were observed in 58.3% (49/84), and lymph node metastasis was present in 58.3% (49/84). ER, PR, and HER2/neu positivity were observed in 59.5%, 53.6%, and 29.8% of cases, respectively. The hormone receptor (HR)-positive/HER2-negative subgroup was the most common (59.5%), followed by HR-positive/HER2-positive (17.9%), HR-negative/HER2-positive (11.9%), and triple-negative (10.7%) subgroups. On descriptive analysis, HR positivity decreased with increasing tumor grade and nodal positivity, whereas HER2/neu positivity increased.
conclusionHistopathological evaluation combined with ER, PR, and HER2/neu immunohistochemistry provides important information for tumor classification, prognostic assessment, and therapeutic decision-making in breast carcinoma. Routine integrated reporting is essential for individualized management of malignant breast lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.